General Information |
| Summary |
The goal of this clinical trial is to learn about the safety of NouvNeu001 injection in Early-onset Parkinson's Disease (EOPD) patients. It will also learn about the effects of NouvNeu001 treatment. The main questions it aims to answer are:
What medical problems do participants have when transplanting NouvNeu001 into bilateral putamen using stereotactic neurosurgery? Does injection of NouvNeu001 improve the motor function and non-motor function in participants?
Participants will:
Be injectioned the NouvNeu001 into bilateral putamen using stereotactic neurosurgery.
Take immunosuppressants to prevent potential immune rejection for 24 to 36 weeks. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2024-08-23 |
| End date (estimated) |
2027-03-01 |
| Clinical feature |
| Label |
Parkinson's disease |
| Link |
http://purl.obolibrary.org/obo/DOID_14330 |
| Description |
A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT06608355 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06608355 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/study/NCT06608355 |
| Sponsors |
iRegene Therapeutics Co., Ltd.
|
Cells |
| Which differentiated cell type is used |
| Label |
dopaminergic neuron |
| Link |
http://purl.obolibrary.org/obo/CL_0000700 |
| Description |
A neuron that releases dopamine as a neurotransmitter. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
6 |
